We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




In Vivo Molecular Imaging Agents Help in Early Disease Detection and Treatment

By Biotechdaily staff writers
Posted on 29 Mar 2007
A new line of imaging agents for in vivo molecular imaging applications allows non-invasive measurement of biologic processes within a living organism. More...
In contrast to conventional diagnostic imaging that highlights conditions caused by disease, molecular imaging identifies molecular abnormalities that are the basis of disease at a very early stage, which can accelerate the development of treatment alternatives that could help cure that disease.

Once attached to a molecule and injected into an organism, X-Sight imaging agents, developed by Eastman Kodak Molecular Imaging Systems group (Rochester, NY, USA), will travel to the target (such as a tumor) and highlight the region of interest. X-Sight imaging agents are non-toxic, making them safe for research studies in areas such as oncology, cardiology, diabetes, and inflammation. They are uniquely designed to provide significant advantages over currently available agents, enabling researchers to perform innovative research studies that could lead to a better understanding of the origin of these diseases.

X-Sight imaging agents deliver excellent brightness and enhanced stability, providing researchers a versatile platform for molecular imaging. These imaging agents are available in several distinct varieties and can be adapted to a wide range of applications.

"The launch of X-Sight Imaging Agents is a significant milestone toward offering our customers a complete solution of systems and agents to advance their research,” commented Shahram Hejazi, Ph.D., worldwide general manager of Kodak's Molecular Imaging Systems division. "This introduction strengthens our leadership in the molecular imaging arena as we move forward to bridge the gap between preclinical and clinical applications.”

X-Sight imaging agents are currently available for preclinical use in the United States and will be launched worldwide in March 2007. Kodak plans to introduce additional imaging agents throughout 2007.

Kodak's Molecular Imaging Systems group--part of Kodak's Health Group--develops and markets high performance digital imaging systems, imaging agents, film, and accessories for the life science research and drug discovery industries.


Related Links:
Kodak

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.